

Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials

Zhang X, et al. *Cardiovasc Ther.* 2020; 2020: 3987065.

- In this study, 7 different statin monotherapy treatments in 50 studies (51,956 participants) were used for the network meta-analyses.
- The statins included simvastatin (SIM), fluvastatin (FLU), atorvastatin (ATO), rosuvastatin (ROS), lovastatin (LOV), pravastatin (PRA), and pitavastatin (PIT).
- In terms of LDL-C lowering, rosuvastatin ranked 1st while fluvastatin ranked 1st in HDL-C-increasing efficacy.
- The comparative treatment efficacy for LDL-C lowering was ROS > ATO > PIT > SIM > PRA > FLU > LOV.

It can be concluded that Rosuvastatin ranked 1st in LDL-C, Apo B-lowering efficacy and ApoA1-increasing efficacy.

